Teriparatide Trickles In For Richter
Forsteo Rival Posts Sales Of €4.8m Following Launches In August
Executive Summary
Richter’s Terrosa biosimilar to Lilly’s Forsteo teriparatide brand made a modest start in Europe. But the Hungarian group still posted nine-month Pharmaceutical sales growth of 8.1%.
You may also be interested in...
Stada Says Teriparatide Roll-Out Has Been Successful
Seven months after introducing its teriparatide biosimilar to Eli Lily’s Forsteo into many European markets, Stada is pleased with results and says doctors and patients alike have responded well.
Gedeon Richter Sees Profit Jump By 40%
A strong tailwind from antipsychotic drug Vraylar helped Hungary’s Gedeon Richter to post a 40% leap in 2019 net profit. Analysts see more upside ahead for eastern Europe’s largest drugmaker.
Mochida Debuts Japanese Teriparatide Biosimilar
Mochida has launched the first Japanese teriparatide biosimilar rival to Eli Lilly’s blockbuster osteoporosis drug Forteo. The company is hoping for big sales for the injectable in the country where the government is aiming to rein in healthcare costs for its rapidly ageing population.